Literature DB >> 6218079

Left ventricular hypertrophy and function in high, normal, and low-renin forms of essential hypertension.

R B Devereux, D D Savage, J I Drayer, J H Laragh.   

Abstract

To assess the relative importance of the level of blood pressure (BP) and renin profile status as determinants of hypertensive left ventricular hypertrophy (LVH) and dysfunction, we studied, by quantitative echocardiography, 118 hypertensive patients off medication. The 19 high-renin patients were younger (31 +/- 13 years; p less than 0.01) but had hypertension of severity (152 +/- 13/95 +/- 11 mg Hg) similar to the 79 normal-renin patients (42 +/- 14 years; 152 +/- 17/98 +/- 12 mg Hg) and 20 low-renin patients (49 +/- 13 yrs; 157 +/- 17/95 +/- 11 mm Hg). Left ventricular (LV) mass index (normal = 70 +/- 25 g/m2) was similar in the high- (113 +/- 21 g/m2, p less than 0.001), normal = (114 +/- 31 g/m2, p less than 0.001), and low-renin patients (115 +/- 18 g/m2, p less than 0.01). End-diastolic relative wall thickness (nl = 0.32 +/- 0.05) was equally elevated in high- (0.41 +/- 0.09), normal (0.42 +/- 0.08) and low-renin groups (0.41 +/- 0.08) (all p less than 0.001). In the entire population, there was a closer correlation of relative wall thickness with total peripheral resistance (r = 0.54, p less than 0.001) than with mean blood pressure (r = 0.31, p less than 0.05). LV dysfunction (LV fractional systolic shortening less than 26%) occurred only in two high-renin patients, whereas LV fractional shortening was significantly increased in the low-renin subgroup (p less than 0.01). We conclude that the degree of LVH is similar in low-, normal-, and high-renin hypertensives and is proportional to the degree of hypertension, even though the high-renin patients were significantly younger; but that the low-renin patients with similar level of blood pressure, even though significantly older and with a longer duration of hypertension than the other patient groups, manifest increased LV function compared to normals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218079     DOI: 10.1161/01.hyp.4.4.524

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs.

Authors:  W Motz; B E Strauer
Journal:  Clin Investig       Date:  1992

Review 2.  Imaging in hypertensive heart disease.

Authors:  Rajesh Janardhanan; Christopher M Kramer
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-02

3.  Contrast in cardiac anatomy and function between black and white patients with hypertension.

Authors:  I W Hammond; M H Alderman; R B Devereux; E M Lutas; J H Laragh
Journal:  J Natl Med Assoc       Date:  1984-03       Impact factor: 1.798

Review 4.  Salt intake, blood pressure, and cardiovascular structure.

Authors:  A H Beil; R E Schmieder; F H Messerli
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

Review 5.  Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.

Authors:  C Morisco; L Argenziano; N Tozzi; A F Mele; B Ricciardelli; G Condorelli; B Trimarco
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Racial differences in cardiac structure and function in essential hypertension.

Authors:  J Mayet; M Shahi; R A Foale; N R Poulter; P S Sever; S A McG Thom
Journal:  BMJ       Date:  1994-04-16

Review 7.  Hypertension in the elderly: age- and disease-related complications and therapeutic implications.

Authors:  E G Lakatta; J D Cohen; J L Fleg; E D Frohlich; A H Gradman
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

Review 8.  Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review.

Authors:  B Dahlöf
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Effect of comorbidities and medications on left ventricular mass regression after bariatric surgery.

Authors:  Mohsin Syed; Mikhail Torosoff; Carl Rosati; Sharon Alger; Steven Fein
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-03       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.